{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:34:57Z","timestamp":1791293697889,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jaci.2023.05.014","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T11:01:57Z","timestamp":1685790117000},"page":"1121-1130.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A\u00a0randomized controlled trial"],"prefix":"10.1016","volume":"152","author":[{"given":"Salman","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally E.","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Bozik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald G.","family":"Archibald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven I.","family":"Dworetzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Killingsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Ghearing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei I.","family":"Ochkur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynold A.","family":"Panettieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3917-3326","authenticated-orcid":false,"given":"Calman","family":"Prussin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2023.05.014_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02094-2020","article-title":"Trends in worldwide asthma prevalence","volume":"56","author":"Asher","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2023.05.014_bib2","series-title":"Global Strategy for Asthma Management and Prevention","year":"2019"},{"key":"10.1016\/j.jaci.2023.05.014_bib3","first-page":"3","article-title":"Asthma prevalence and management in adults in France in 2018: ASTHMAPOP survey","volume":"52","author":"Raherison-Semjen","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2023.05.014_bib4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaip.2019.08.024","article-title":"Trends and disparities in asthma biologic use in the United States","volume":"8","author":"Inselman","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.05.014_bib5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.anai.2020.04.004","article-title":"Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma","volume":"125","author":"Moore","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.05.014_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1755-5949.2008.00048.x","article-title":"KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis","volume":"14","author":"Gribkoff","year":"2008","journal-title":"CNS Neurosci Ther"},{"issue":"1 Supplement","key":"10.1016\/j.jaci.2023.05.014_bib7","first-page":"P04.150","article-title":"Human dopamine receptor affinity and potency in vitro and dose tolerability in beagle dogs in vivo of dexpramipexole and pramipexole","volume":"78","author":"Gribkoff","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2023.05.014_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bcmd.2017.01.008","article-title":"The targeted eosinophil-lowering effects of dexpramipexole in clinical studies","volume":"63","author":"Dworetzky","year":"2017","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jaci.2023.05.014_bib9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","article-title":"Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes","volume":"132","author":"Panch","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.05.014_bib10","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/lary.27564","article-title":"Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size","volume":"129","author":"Laidlaw","year":"2019","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2023.05.014_bib11","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2023.05.014_bib12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/all.15481","article-title":"Urine eosinophil-derived neurotoxin: a potential marker of activity in select eosinophilic disorders","volume":"78","author":"Makiya","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.05.014_bib13","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/all.12206","article-title":"Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia","volume":"68","author":"Nair","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.05.014_bib14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/all.12817","article-title":"Nasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophilia","volume":"71","author":"Rank","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.05.014_bib15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.05.014_bib16","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.05.014_bib17","series-title":"Pulmonary function laboratories: advice regarding COVID-19 (March 2020)","year":"2020"},{"key":"10.1016\/j.jaci.2023.05.014_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2023.05.014_bib19","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.05.014_bib20","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.05.014_bib21","series-title":"NUCALA (mepolizumab) prescribing information","year":"2021"},{"key":"10.1016\/j.jaci.2023.05.014_bib22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1146\/annurev-immunol-093019-125918","article-title":"Eosinophil knockout humans: uncovering the role of eosinophils through eosinophil-directed biological therapies","volume":"39","author":"Jacobsen","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2023.05.014_bib23","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1164\/rccm.201611-2234OC","article-title":"Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma","volume":"196","author":"Kelly","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2023.05.014_bib24","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaip.2020.08.039","article-title":"Clinical development of mepolizumab for the treatment of severe eosinophilic asthma: on the path to personalized medicine","volume":"9","author":"Pavord","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.05.014_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00935-2021","article-title":"Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma","volume":"59","author":"Van Hulst","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2023.05.014_bib26","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2023.05.014_bib27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.05.014_bib28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1152\/japplphysiol.00329.2007","article-title":"Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation","volume":"104","author":"Sorkness","year":"2008","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.jaci.2023.05.014_bib29","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2023.05.014_bib30","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2023.05.014_bib31","doi-asserted-by":"crossref","first-page":"eaau7148","DOI":"10.1126\/sciimmunol.aau7148","article-title":"Identification of two distinct pathways of human myelopoiesis","volume":"4","author":"Drissen","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2023.05.014_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102913","article-title":"Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma","volume":"24","author":"Hassani","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jaci.2023.05.014_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12948-020-00138-1","article-title":"Dexamethasone and lidocaine suppress eosinophilopoiesis from umbilical cord blood cells","volume":"18","author":"Muraki","year":"2020","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.jaci.2023.05.014_bib34","doi-asserted-by":"crossref","first-page":"AB126","DOI":"10.1016\/j.jaci.2022.12.399","article-title":"Generation of functionally competent eosinophils and eosinophil precursors using an induced pluripotent stem cell model","volume":"151","author":"Constantine","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.05.014_bib35","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","article-title":"Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial","volume":"12","author":"Cudkowicz","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaci.2023.05.014_bib36","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2023.05.014_bib37","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2023.05.014_bib38","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"American Thoracic Society, European Respiratory Society. ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2023.05.014_bib39","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/all.12206","article-title":"Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia","volume":"68","author":"Nair","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.05.014_bib40","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/all.12817","article-title":"Nasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophilia","volume":"71","author":"Rank","year":"2016","journal-title":"Allergy"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923007091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923007091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:43:44Z","timestamp":1758793424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674923007091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0091674923007091"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2023.05.014","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A\u00a0randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}